Under construction – not a live service
Sign in
Not yet recruitingPhase 1

Neutralizing Interferon Type 1 in Hidradenitis Suppurativa

Key facts

Who runs it
Centre Hospitalier Universitaire de Besancon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
6 people, planned
Started
Sept 2025
Planned end
Sept 2026
Type of study
Interventional
Treatments tested
  • Plasma with neutralizing autoantibodies to Type I Interferons
Record updated
16 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Men and women aged over 18
  • Patients with Hidradenitis suppurativa (Hurley stages II-III)
  • Disease affecting at least two distinct anatomical areas,
  • Total count of abscesses (A) and inflammatory nodules (N) ≥ 3
  • IHS4 score ≥ 11
  • Treatment of pain with opioids (≥ 20 mg/day)
  • Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab)
  • Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure)
  • Women using an effective method of contraception
  • Signed informed consent

Who cannot take part

  • Active viral infection: herpes, VZV, HIV, HBV, HCV
  • Active bacterial infection requiring systemic antibiotics
  • Known allergy to blood components/plasma proteins
  • Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction < 40%)
  • Pregnant women
  • Subjects with no social security coverage

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer anti-IFN-1 autoantibodies.

The group in the trial

  • Patients with severe acute flare Hurley stage III HSTreatment being tested

    These patients present with refractory severe HS (Hurley stage III) flare treated with a transfusion of plasma containing high titre anti-IFN-1 auto-Antibodies.

    Treatment: Plasma with neutralizing autoantibodies to Type I Interferons

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Use of Plasma With Neutralizing Autoantibodies to Type I Interferons in Patients With Severe Refractory Flare-up of Hidradenitis Suppurativa
Record updated
16 July 2025